Competition Induced Hyperglycemia in Athletes With Type 1 Diabetes

NCT ID: NCT05561517

Last Updated: 2023-10-25

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

24 participants

Study Classification

INTERVENTIONAL

Study Start Date

2023-05-01

Study Completion Date

2024-09-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Design and methods 12 athletes with T1D and 12 healthy athletes are included in a prospective experimental randomized, cross-over study. Athletes are provided with a Dexcom G6 CGM to measure glucose excursions before, during and after exercise and a Holter ECG-E-patch to measure HRV. Psychological stress levels are assessed from Competitive State Anxiety Inventory-2.

The athletes are studied on two occasions: Day 1: 5K running competition and Day 2: 5K high intensity training session (running) in the athletes' regular training environment.

Endpoints Primary endpoints: Change in plasma glucose from start of exercise to end of exercise during competition compared to training.

Secondary endpoints: Hormonal response (cortisol, adrenalin, noradrenaline). Changes in heart rate and HRV before, during and after exercise. CGM-glucose and plasma glucose discrepancies.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Design 12 athletes with T1D and 12 healthy athletes are included in a prospective experimental randomized, cross-over study.

Screening visit Investigator Rakel Fuglsang Johansen will orally inform eligible athletes about the study at the screening visit at Steno Diabetes Center Aarhus. Individuals who have agreed to join the study (given oral and written informed consent), will have a short physically examination performed including measurement of blood pressure, height, weight, and heart and lung auscultation and screening blood samples (kidney, liver, and blood counts, lipids, and HbA1c) will be taken.

Prior to study days Within 1 month prior to the 1st study day, eligible participants will also be invited to perform a maximal incremental test to volitional exhaustion to determine their individual VO2 max. The test will be performed on a treadmill.

The athletes come to the outpatient clinic 2 days prior to the 1st study day (training or competition), where they are provided with a Dexcom G6 CGM to measure glucose excursions before, during and after exercise and a Holter ECG-E-patch to measure HRV. Instructions on food and liquid intake prior to study days are provided.

The participants are required to refrain from any intense or prolonged physical activity and alcohol consumption 48 hours prior to study days and instructed to consume a weight maintaining diet according to recommended guidelines (approx. 20 % fat, 30 % protein and 50 % carbohydrate). The participants are asked to keep a food diary and to match their food intake as accurate as possible before the two study days.

Participants with T1D should not change their insulin treatment or strategies prior to or during the study days. If the participant has experienced severe hypoglycemia (glucose measurement below 2.8 mmol/L) within 24 h hours before the study day, a new study day will be arranged. This in order to avoid that upstream hypoglycemia will affect the glucoregulatory responses during the study day, and because of the increased risk of a new hypoglycemic events.

Study days The athletes participate in a competition day and a training day in randomized order.

On the competition day, the athletes participate in a 5 km race. The last meal must be consumed at least 2 hours before the competition and the athlete is not allowed to consume anything until 1 hour after the completion of the competition, where the last blood sample will be taken. Participants with T1D should adhere to the same fasting period, but if this is not possible due to hypoglycemia, then the type and amount of food/fluid intake is recorded.

Twenty minutes before the start of the competition the initial blood samples are taken. After the athlete has completed the competition, blood sampling is repeated after 10, 20, 30, and 60 minutes. At each time point, blood samples for measurement of hormonal response (cortisol, adrenalin, noradrenaline, glucagon, insulin, growth hormone) and circulating metabolites (glucose, free fatty acids, glycerol, triglyceride, lactate) are collected. During this period, the athlete is interviewed about dietary intake within the last 24 hours and psychological stress in assessed by use of the Competitive State Anxiety Inventory-2 (SCAI-2) questionnaire. After the last blood sample has been taken, the athlete is allowed to eat and drink as usual, and the study day is completed.

On the training day, the athletes perform a 5 km high-intensity training run, but in the athletes' regular training environment without the element of competition. The time to complete the 5 km is recorded. The training sessions are performed at the same time of the day as on the competition day and the same rules apply as on the competition day regarding food and beverage intake. Blood samples are collected in the same manner as on the competition day. Once again, an interview regarding food intake and stress level is performed.

The competition day and the training day are performed three to six days apart. During the 10-day period where the CGM device is worn, data are recorded in a personal study diary listing start and end of training sessions. Food intake is recorded in the diary 24 prior to and during the study day, as well as hypoglycemic events within this period.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Type 1 Diabetes Hyperglycemia Stress

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

12 athletes with T1D and 12 healthy athletes are included in a prospective experimental randomized, cross-over study.
Primary Study Purpose

OTHER

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Competition

Participation in a 5 K competition (running)

Group Type ACTIVE_COMPARATOR

5 K running

Intervention Type OTHER

The 5 K running competition will induce increased stress levels and thereby lead to increased levels of hyperglycemia.

Training

Performing a 5 K up-tempo training bout (running)

Group Type ACTIVE_COMPARATOR

5 K running

Intervention Type OTHER

The 5 K running competition will induce increased stress levels and thereby lead to increased levels of hyperglycemia.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

5 K running

The 5 K running competition will induce increased stress levels and thereby lead to increased levels of hyperglycemia.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* T1D and healthy athletes who are otherwise healthy
* Age between 18 and 65 years
* HbA1c less than 70 mmol/mol
* The athletes must be engaged in competitive sports that includes running, and agree to participate in a local 5 km running competition within 3 months

Exclusion Criteria

* Proliferative retinopathy
* Hypoglycemia unawareness
* Heart disease and other conditions which may be negatively affected by the VO2 max test and study days
Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University of Aarhus

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Esben Soendergaard

Role: PRINCIPAL_INVESTIGATOR

University of Aarhus

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Steno Diabetes Center Aarhus

Aarhus, Region Midt, Denmark

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Denmark

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

94654

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Model Driven Diabetes Care
NCT01774149 COMPLETED NA
HIT in People With Type 1 Diabetes
NCT03545841 COMPLETED NA
Context Aware Data Gathering Study
NCT04154904 COMPLETED NA